Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review

被引：7
作者：
Domingues, Gerson [1 ,4 ]
Chinzon, Decio [2 ]
Moraes-Filho, Joaquim Prado P. [2 ]
Senra, Juliana Tosta [3 ]
Perrotti, Marcos [3 ]
Zaterka, Schlioma [2 ]
机构：
[1] Univ Estado Rio De Janeiro, Med Sch, Internal Med Gastroenterol Dept, Rio De Janeiro, Brazil
[2] Univ Sao Paulo, Med Sch, Gastroenterol Dept, Sao Paulo, Brazil
[3] Takeda Pharmaceut, Sao Paulo, Brazil
[4] Univ Estado Rio De Janeiro, Med Sch, Internal Med Gastroenterol Dept, Av Ayrton Senna 1850,Sala 224 Barra Tijuca RJ, Rio De Janeiro, Brazil
来源：
GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY | 2023年 / 18卷 / 01期
关键词：
gastroesophageal reflux; antacids; proton pump inhibitors; P-CABs; vonoprazan; RANDOMIZED CLINICAL-TRIAL; VS; LANSOPRAZOLE; VONOPRAZAN; MAINTENANCE; FUMARATE; EFFICACY; TAK-438;
D O I：
10.5114/pg.2022.116673
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Introduction: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency - ANVISA.Aim: This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fu-marate.Material and methods: A literature search was conducted through April-May 2021 using official databases with a combi-nation of MeSH controlled vocabulary and text words. The authors selected articles that described pivotal and novel insights about P-CABs and vonoprazan fumarate.Results: Vonoprazan is a drug of the P-CABs class newly approved for the management of acid-related diseases in Brazil. P-CABs achieve rapid, potent, and prolonged acid suppression (including night-time) and promise to address some unmet clinical needs in GERD. Furthermore, considering the difficulties encountered in attaining effective symptomatic control - particularly at night - using currently available PPIs, this new drug class is promising.Conclusions: This review brings important information about vonoprazan, a new therapeutic option in Brazil, which may be considered as a valuable tool for managing acid-related diseases.
引用
收藏
页码：47 / 55
页数：9
相关论文
共 41 条
[31]   Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects [J].
Sakurai, Yuuichi ;
Nishimura, Akira ;
Kennedy, Gale ;
Hibberd, Mark ;
Jenkins, Richard ;
Okamoto, Hiroyuki ;
Yoneyama, Tomoki ;
Jenkins, Helen ;
Ashida, Kiyoshi ;
Irie, Shin ;
Taeubel, Joerg .
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2015, 6
[32]   The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease [J].
Scarpignato, Carmelo ;
Hunt, Richard H. .
CURRENT OPINION IN GASTROENTEROLOGY, 2019, 35 (04) :344-355
[33]   Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors [J].
Shibli F. ;
Kitayama Y. ;
Fass R. .
Current Gastroenterology Reports, 2020, 22 (4)
[34]   Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis [J].
Tanabe, Tomohide ;
Hoshino, Shintaro ;
Kawami, Noriyuki ;
Hoshikawa, Yoshimasa ;
Hanada, Yuriko ;
Takenouchi, Nana ;
Goto, Osamu ;
Kaise, Mitsuru ;
Iwakiri, Katsuhiko .
ESOPHAGUS, 2019, 16 (04) :377-381
[35]  
The National Institute for Health and Care Excellence (NICE), 2020, MAN PEPT ULC DIS AD, V37
[36]   Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis [J].
Umezawa, Mariko ;
Kawami, Noriyuki ;
Hoshino, Shintaro ;
Hoshikawa, Yoshimasa ;
Koizumi, Eriko ;
Takenouchi, Nana ;
Hanada, Yuriko ;
Kaise, Mitsuru ;
Iwakiri, Katsuhiko .
DIGESTION, 2018, 97 (04) :309-315
[37]  
World Gastroenterology Organisation (WGO), 2015, WORLD GASTROENTEROLO, P1
[38]   Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis [J].
Xiao, Yinglian ;
Zhang, Shutian ;
Dai, Ning ;
Fei, Guijun ;
Goh, Khean-Lee ;
Chun, Hoon Jai ;
Sheu, Bor-Shyang ;
Chong, Chui Fung ;
Funao, Nobuo ;
Zhou, Wen ;
Chen, Minhu .
GUT, 2020, 69 (02) :224-230
[39]   Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases [J].
Yang, Xiaoxiao ;
Li, Yueyue ;
Sun, Yiyuan ;
Zhang, Mingming ;
Guo, Chuanguo ;
Mirza, Iqtida Ahmed ;
Li, Yan-Qing .
DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (02) :302-311
[40]   Long-term proton pump inhibitor therapy and risk of hip fracture [J].
Yang, Yu-Xiao ;
Lewis, James D. ;
Epstein, Solomon ;
Metz, David C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2947-2953
12345